5-Methyl-5,6,7,8-tetrahydroquinoxalin | 52517-54-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-Methyl-5,6,7,8-tetrahydroquinoxalin
• 英文别名: 5-methyl-5,6,7,8-tetrahydro-quinoxaline；5,6,7,8-Tetrahydro-5-methylquinoxaline；5-methyl-5,6,7,8-tetrahydroquinoxaline
• CAS: 52517-54-1
• 化学式: C₉H₁₂N₂
• 分子量: 148.208
• InChiKey: JPKFXMPIYYDRJK-UHFFFAOYSA-N

物化性质

• LogP：
  1.900 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• NOVEL FAP INHIBITORS
  申请人：UNIVERSITEIT ANTWERPEN

  公开号：US20140357650A1

  公开（公告）日：2014-12-04

  The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.

  本发明涉及具有高选择性和特异性的新型抑制剂，用于FAP（成纤维细胞激活蛋白）。所述抑制剂可用作人类和/或兽医药物，特别用于治疗和/或预防与FAP相关的疾病，如但不限于增殖性疾病。
• [EN] SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS<br/>[FR] 2-QUINOLYLE-OXAZOLES SUBSTITUÉS UTILES COMME INHIBITEURS DU PDE4
  申请人：SCHERING CORP

  公开号：WO2005116009A1

  公开（公告）日：2005-12-08

  The invention claims compounds of the: (formula I); wherein: (formula II) is a 5-membered heteroaryl; X is S or O; R1 is H, alkyl, cycloalkyl, cylcoalkylalkyl-, -CH2F, -CHF2, -CF3, -C(O)alkyl or -C(O)NR18R19; R3 and R4 H, alkyl, hydroxyalkyl or -C(O)Oalkyl; R5 and R6 are H, alkyl, hydroxyalkyl, alkoxyalkyl, mercaptoalkyl, -CH2F, -CHF2, -CF3, -C(O)OH or -C(O)Oalkyl; R7 is H, alkyl, alkenyl, hydroxyalkyl, cycloalkyl, alkoxyalkyl, aminoalkyl, (R17-phenyl)alkyl or -CH2-C(O)-O-alkyl; and R8 comprises alkyl, heteroaryl, phenyl or cycloalkyl, or heterocycloalkyl, all optionally substituted, or a cycloalkyl- or heterocycloalkyl-substituted amide; or R7 and R8 and the nitrogen to which they are attached together form an optionally substituted ring; and the remaining variables are as defined in the specification. Also claimed are pharmaceutical compositions, the use of the compounds as PDE4 inhibitors, and combinations with other actives.

  该发明声明了以下化合物：(化学式I)；其中：(化学式II)是一种5-成员杂环芳基；X为S或O；R1为H，烷基，环烷基，环烷基烷基，-CH2F，-CHF2，-CF3，-C(O)烷基或-C(O)NR18R19；R3和R4为H，烷基，羟基烷基或-C(O)O烷基；R5和R6为H，烷基，羟基烷基，烷氧基烷基，巯基烷基，- ，- ，- ，-C(O)OH或-C(O)O烷基；R7为H，烷基，烯基，羟基烷基，环烷基，烷氧基烷基，氨基烷基，(R17-苯基)烷基或-CH2-C(O)-O-烷基；R8包括烷基，杂环芳基，苯基或环烷基，或杂环烷基，均可选择性取代，或环烷基或杂环烷基取代的酰胺；或R7和R8及它们附着的氮一起形成一个可选择性取代的环；其余变量如规范中所定义。还声明了药物组合物，将这些化合物用作PDE4抑制剂，并与其他活性物质组合使用。
• PERHYDROQUINOXALINE DERIVATIVES
  申请人：DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL

  公开号：US20160122307A1

  公开（公告）日：2016-05-05

  The present invention relates to perhydroquinoxaline compounds according to the general formula (1), their use as a medicament, in particular as analgesic, antipruritic and anti-inflammatory agents, and their preparation.

  本发明涉及通式（1）的过氢化喹喔啉化合物，它们作为药物的用途，特别是作为镇痛剂、止痒剂和抗炎剂，以及它们的制备方法。
• Respiratory syncytial virus replication inhibitors
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1400519B1

  公开（公告）日：2007-03-07